<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734237</url>
  </required_header>
  <id_info>
    <org_study_id>IDCRP-120</org_study_id>
    <secondary_id>AAI1201200007000</secondary_id>
    <nct_id>NCT03734237</nct_id>
  </id_info>
  <brief_title>A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD</brief_title>
  <acronym>PAIVED</acronym>
  <official_title>A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry M. Jackson Foundation for the Advancement of Military Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defense Health Agency Immunization Healthcare Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armed Forces Health Surveillance Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naval Health Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Air Force School of Aerospace Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry M. Jackson Foundation for the Advancement of Military Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 15,000 eligible subjects (or 5,000subject distributed evenly between the 3 study&#xD;
      arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based&#xD;
      vaccine, the recombinant vaccine, or the egg-based vaccine) over two influenza seasons&#xD;
      (2018-2019, 2019-2020, 2020-2021).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This tree-year, pragmatic, prospective study will compare the effectiveness of licensed&#xD;
      egg-based inactivated influenza vaccines to the effectiveness of two other types of licensed&#xD;
      vaccines, the cell-culture based inactivated influenza vaccine and the recombinant influenza&#xD;
      vaccine, in the prevention of laboratory-confirmed influenza infection in active duty&#xD;
      members, military retirees, and other DoD beneficiaries. Military treatment facilities (MTFs)&#xD;
      in the United States will participate in this protocol. Enrollment will be restricted to&#xD;
      adults (â‰¥18 years and older) who are preparing to receive seasonal influenza vaccination at&#xD;
      participating DoD sites. Subjects will be randomized to receive one of the three licensed&#xD;
      influenza vaccines types for evaluation of effectiveness. There is no exclusion for&#xD;
      pregnancy, as none of these licensed products are contraindicated in pregnant women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 15,000 eligible subjects (or 5,000 subject distributed evenly between the 3 study arms) will be enrolled. eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over three influenza seasons (2018-2019,2019-2020, 2020-2021,).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory confirmed influenza attack rates</measure>
    <time_frame>Onset &gt; 13 days after vaccination up to 1 year</time_frame>
    <description>Laboratory-confirmed influenza as ascertained by a sensitive and specific assay is needed to assess effectiveness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) titer responses to vaccine and circulating strains of influenza</measure>
    <time_frame>Baseline to 21-35 days post vaccine</time_frame>
    <description>A subset of volunteers may participate it in this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudovirion neutralization (PVN) responses to vaccine and circulating strains of influenza</measure>
    <time_frame>Baseline to 21-35 days post vaccine</time_frame>
    <description>A subset of volunteers may participate it in this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Neuraminidase (Anti-NA) titer responses to vaccine and circulating strains of influenza</measure>
    <time_frame>Baseline to 21-35 days post vaccine</time_frame>
    <description>A subset of volunteers may participate it in this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Responses: Frequency of antigen specific CD4 and CD8 cells, B cells</measure>
    <time_frame>Baseline to 21-35 days post vaccine</time_frame>
    <description>A subset of volunteers may participate it in this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Influenza-like Illness</measure>
    <time_frame>Onset &gt; 13 days after vaccination up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of influenza confirmed hospitalization</measure>
    <time_frame>Onset &gt; 13 days after vaccination up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of duty (work) days lost due to Influenza-like Illness</measure>
    <time_frame>Onset &gt; 13 days after vaccination up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tertiary Arm- Assess the burden of covid-19 and explore the inter-relationship between influenza and covid-19</measure>
    <time_frame>onset &gt;13 days after vaccination</time_frame>
    <description>Endpoints: incidence of COVID-19 incidence of co-infection with influenza &amp; Severity of COVID-19, symptoms associated with COVID-19 infection (compared with influenza, other respiratory viruses)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza-like Illness</condition>
  <arm_group>
    <arm_group_label>Egg based influenza vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombinant influenza vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cell-culture based influenza vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg based influenza vaccines</intervention_name>
    <description>Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.</description>
    <arm_group_label>Egg based influenza vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant influenza vaccines</intervention_name>
    <description>Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.</description>
    <arm_group_label>Recombinant influenza vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-culture based influenza vaccines</intervention_name>
    <description>Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.</description>
    <arm_group_label>Cell-culture based influenza vaccines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible for care in Department of Defense medical facilities (Defense Enrollment&#xD;
             Eligibility Reporting System eligible)&#xD;
&#xD;
          2. â‰¥18 years of age.&#xD;
&#xD;
          3. At a participating Military Treatment Facility site for the purpose of receiving a&#xD;
             seasonal (2018-2019, 2019-2020,2020-2021) influenza vaccination.&#xD;
&#xD;
          4. Able to speak English and able to provide informed consent&#xD;
&#xD;
          5. Able to receive and respond to texts and/or emails, or a military recruit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adults intending to receive or who have received the current seasons FluMist Vaccine&#xD;
             (LAIV)&#xD;
&#xD;
          2. Adults who have already received a flu vaccine within the current season&#xD;
&#xD;
          3. Individual who cannot receive a flu vaccine or standard dosing due to another medical&#xD;
             condition&#xD;
&#xD;
          4. Allergic to gentamicin, polymyxin and/or neomycin&#xD;
&#xD;
          5. Individuals who fail to meet the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Burgess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniformed Services University of the Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Coles, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Infectious Diseases Clinical Research Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Spevak, BSHS</last_name>
    <phone>240-694-2067</phone>
    <email>mspevak@hjf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Moreno</last_name>
    <phone>1-877-328-4258</phone>
    <email>nmoreno@idcrp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>34800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Cammarata</last_name>
      <phone>619-532-7483</phone>
      <email>stephanie.m.cammarata.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Gregory Utz, MD</last_name>
      <phone>619.532.8288</phone>
      <email>gregory.utz.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Maves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United States Naval Academy</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantele Friend</last_name>
      <email>cfriend@idcrp.org</email>
    </contact>
    <contact_backup>
      <last_name>Steven Fix, MPH</last_name>
      <email>sfix@idcrp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jitendrakumar Modi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USU</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Pratt</last_name>
      <email>LPratt@idcrp.org</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Moreno</last_name>
      <email>nmoreno@idcrp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Allan Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irma Barahona</last_name>
      <phone>301-319-8673</phone>
      <email>irma.l.barahona.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Anuradha Ganesan</last_name>
      <phone>301.295.2972</phone>
      <email>anuradha.ganesan.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Casey Geaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Womack Army Medical Center</name>
      <address>
        <city>Fort Bragg</city>
        <state>North Carolina</state>
        <zip>28310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Spooner</last_name>
      <phone>858-361-4706</phone>
      <email>christina.e.spooner.civ@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Bruce McClenathan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carl R. Darnall Army Medical Center</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76544</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Duran</last_name>
      <email>laurie.l.duran.civ@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Deleon</last_name>
      <email>stephanie.deleon.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>David Hrncir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjuanita Medina</last_name>
      <phone>210-916-7913</phone>
      <email>sanjuanita.s.medina.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Mende, PhD</last_name>
      <phone>210.916.3859</phone>
      <email>katrin.mende.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Ana E Markelz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lackland Airforce Base</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Swarthout ebard, RN</last_name>
      <email>amy.l.swarthoutebard.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Deleon</last_name>
      <email>stephanie.deleon.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Catherine Skerrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rezalina Tant</last_name>
      <phone>757-953-5603</phone>
      <email>rezalina.g.tant.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Realisha Smith</last_name>
      <email>realisha.b.smith.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Tahaniyat Lalani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Chambers</last_name>
      <phone>253-968-1643</phone>
      <email>susan.e.chambers4.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Rhonda Colombo</last_name>
      <phone>253-968-4596</phone>
      <email>rhonda.e.colombo.ctr@mail.mil</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Schofield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/flu/index.htm</url>
    <description>Influenza. Centers for Disease Control and Prevention</description>
  </link>
  <link>
    <url>https://www.cdc.gov/flu/weekly/index.htm</url>
    <description>CDC. FluView. 2017-2018 Influenza Season Week 13 ending March 31, 2018.</description>
  </link>
  <reference>
    <citation>Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA. Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev. 2015 Jul;28(3):743-800. doi: 10.1128/CMR.00039-14. Review.</citation>
    <PMID>26085551</PMID>
  </reference>
  <reference>
    <citation>Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2.</citation>
    <PMID>29447141</PMID>
  </reference>
  <reference>
    <citation>Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583. doi: 10.1073/pnas.1712377114. Epub 2017 Nov 6.</citation>
    <PMID>29109276</PMID>
  </reference>
  <reference>
    <citation>Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017 Oct 23;13(10):e1006682. doi: 10.1371/journal.ppat.1006682. eCollection 2017 Oct.</citation>
    <PMID>29059230</PMID>
  </reference>
  <reference>
    <citation>Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.</citation>
    <PMID>24667168</PMID>
  </reference>
  <reference>
    <citation>Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, Halpin RA, Lin X, Stockwell TB, Das SR, Landon E, Tesic V, Youngster I, Pinsky BA, Wentworth DE, Hensley SE, Grad YH. Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013. Clin Infect Dis. 2018 Jul 18;67(3):327-333. doi: 10.1093/cid/ciy097.</citation>
    <PMID>29471464</PMID>
  </reference>
  <reference>
    <citation>Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z, Hancock K, Weiss CD. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods. 2008 Nov;153(2):111-9. doi: 10.1016/j.jviromet.2008.07.015. Epub 2008 Sep 4.</citation>
    <PMID>18722473</PMID>
  </reference>
  <reference>
    <citation>Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J Virol Methods. 2010 May;165(2):305-10. doi: 10.1016/j.jviromet.2010.02.009. Epub 2010 Feb 11.</citation>
    <PMID>20153374</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigative team members with knowledge and experience with statistical and scientific procedures will de-identify PHI and prepare the data set to be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

